Overview

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study was to be conducted as a multi-centre, randomized, investigator-blinded, active and vehicle-controlled, intra-individual (split-face/scalp) non-inferiority (regarding efficacy) and superiority (regarding pain) study. The primary purpose of this study is to demonstrate the non-inferiority of NDL-PDT compared to c-PDT in terms of lesion complete response rate.
Phase:
Phase 3
Details
Lead Sponsor:
Galderma
Galderma R&D
Treatments:
Aminolevulinic Acid
Methyl 5-aminolevulinate